Cellular Biomedicine Group (CBMG) Earns Media Sentiment Rating of 0.30
News articles about Cellular Biomedicine Group (NASDAQ:CBMG) have trended positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.30 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.3765419803333 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, Maxim Group set a $18.00 price target on shares of Cellular Biomedicine Group and gave the company a “buy” rating in a research report on Tuesday, August 29th.
Shares of Cellular Biomedicine Group (CBMG) opened at 11.0655 on Wednesday. The firm’s 50-day moving average is $9.24 and its 200 day moving average is $9.47. The firm’s market capitalization is $156.11 million. Cellular Biomedicine Group has a one year low of $5.05 and a one year high of $15.45.
Cellular Biomedicine Group declared that its Board of Directors has initiated a stock buyback plan on Thursday, June 1st that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: “Cellular Biomedicine Group (CBMG) Earns Media Sentiment Rating of 0.30” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/13/cellular-biomedicine-group-cbmg-earns-media-sentiment-rating-of-0-30.html.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Stock Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related stocks with our FREE daily email newsletter.